Atlas Trials

Respiratory Syncytial Virus Infections

172 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Respiratory Syncytial Virus Infections

RecordFirmDate
Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) (NCT01065935)Alnylam Pharmaceuticals2010-02-01
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) (NCT00658086)Alnylam Pharmaceuticals2008-04-01
Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly (NCT00609635)West Penn Allegheny Health System2007-11-01
Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus (NCT00496821)Alnylam Pharmaceuticals2007-07-01
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age (NCT00493285)MedImmune LLC2007-07-01
Safety Study of Oral BTA9881 to Treat RSV Infection (NCT00504907)Biota Scientific Management Pty Ltd2007-07-01
Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants (NCT00384462)MedImmune LLC2006-10-01
Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season (NCT00316264)MedImmune LLC2006-04-01
Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy (NCT00420966)Sunnybrook Health Sciences Centre2005-10-01
A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT (NCT00232635)Arrow Therapeutics2005-09-01
Study to Evaluate MEDI-534 in Healthy Adults (NCT00111878)MedImmune LLC2005-04-01
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children (NCT00129766)MedImmune LLC2004-11-01
Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524 (NCT00192478)MedImmune LLC2004-02-01
Assessment of Airway Obstruction in Infants With Lower Respiratory Infections (NCT00435994)Indiana University2003-12-01
Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults (NCT00192465)MedImmune LLC2003-11-01
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany (NCT01155193)AbbVie (prior sponsor, Abbott)2002-09-01
Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients (NCT00031473)National Institute of Allergy and Infectious Diseases (NIAID)1997-11-01
← Previous

Track Respiratory Syncytial Virus Infections automatically

Every clearance here is in the API, with alerts when new ones post.